



Product Description

Ensartinib hydrochloride

Catalog No: tcsc0043455

Available Sizes
Size: 2mg
Size: 5mg
Size: 10mg
Specifications
CAS No: 2137030-98-7
Formula: $ {\rm C}_{26}{\rm H}_{29}{\rm Cl}_4{\rm FN}_6{\rm O}_3 $
Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK
Target: c-Met/HGFR;ALK
Purity / Grade: >98%
Solubility: H2O: 5 mg/mL (7.88 mM; Need ultrasonic and warming)
Alternative Names: X-396 hydrochloride
Observed Molecular Weight: 634.36





Ensartinib hydrochloride (X-396 hydrochloride) is a potent and dual **ALK/MET** inhibitor with **IC**₅₀s of IC50 & Target: IC50: [1]

In Vitro: Ensartinib (X-396) is a potent and dual ALK/MET inhibitor with IC $_{50}$ s of EML4-ALK E13;A20 (IC $_{50}$: 15 nM). Ensartinib is also potent in H2228 lung cancer cells harboring *EML4-ALK* E6a/b; A20 (IC $_{50}$: 45 nM). Furthermore, X-376 is potent in SUDHL-1 lymphoma cells harboring *NPM-ALK* (IC $_{50}$: 9 nM)^[1].

In Vivo: Ensartinib (X-396) shows substantial bioavailability and moderate half-lives in vivo. Nude mice harboring H3122 xenografts are treated with Ensartinib at 25 mg/kg bid. Ensartinib significantly delays the growth of tumors compared to vehicle alone. In the xenograft experiments, Ensartinib appears well-tolerated in vivo. Mouse weight is unaffected by Ensartinib treatment. Drug-treated mice appear healthy and do not display any signs of compound related toxicity. To further assess potential side effects of Ensartinib, additional systemic toxicity and toxico-kinetic studies are performed in Sprague Dawley (SD) rats. Following 10 days of repeated oral administration of Ensartinib at 20, 40, 80 mg/kg in SD rats, all animals survive to study termination. The no significant toxicity (NST) levels are determined to be 80 mg/kg for Ensartinib. At NST levels, Ensartinib achieves an AUC of 66 μ M×hr and a μ Cmax of 7.19 μ M^[1]

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!